SHENZHEN, China, May 29, 2012 /PRNewswire-Asia/ -- Beike Biotechnology Co., Ltd (“Beike”) announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China‘s first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking.
Ying Song, MD, PhD, Medical Director of Beike, stated, “It is a proud moment for us that Beike is the first and the only stem cell bank in China to possess AABB accreditation for both cord blood and cord tissue and this reflects our commitment to quality. It is also noteworthy to mention that Beike is among the first stem cell banks in the world to receive AABB accreditation for cord tissue banking which positions Beike as a leader in stem cell preservation.”
Beike began the comprehensive AABB accreditation process in March 2010 and completed the on-site assessment in September 2011. The accreditation assessment included stem cell processing, records, document control, inspection and testing, technician training, sample identification, traceability and validations. During this audit, it was determined that Beike’s medical, technical and administrative performance met the standards set by the AABB. Beike was issued its AABB certificate in January 2012.
Dr. Shengqin Ye, President of Beike, commented, “We are extremely pleased to have been granted this accreditation. With this, Beike has once again demonstrated a commitment to advanced learning, continuous improvement and innovation to sustain the highest possible level of quality and safety.”
To meet AABB standards, Beike adopted new technology for stem cell processing (AXP® AutoXpress system), storage (BioArchive® Systems), and testing (Beckman hematology analyzer LH750 and Tecan Freedom EVOlyzer). Additionally, the company optimized its information technology platform and software systems, adding an advanced bar code management system, real-time monitoring capabilities, and an advanced enterprise resource planning (ERP) system to its call center.
About Beike Biotechnology Company:
Shenzhen Beike Biotechnology Co., Ltd. is China‘s leading biotechnology company focusing on banking adult stem cells and developing new cell based medicinal products. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.
About AABB:
AABB (formerlytheAmerican Association of Blood Banks) is an international non-profit body dedicated to developing thehighest standards in blood and cord blood banking, transfusion medicine and cellular therapy.The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.
Based in the United States, AABB represents more than 2,000 institutions and 8,000 individuals in 80 countries, involved in collecting, processing, testing, distributing, or transfusing blood, blood components, or cellular therapy products.
For any questions regarding this release, please call:
Contact Person:
T. Gutmann
Phone Number: +86-532-6677-6659
SOURCE Beike Biotechnology Co. Ltd.
